Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/41079
metadata.artigo.dc.title: Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
metadata.artigo.dc.creator: Kandeel, Mahmoud
Al-Nazawi, Mohammed
metadata.artigo.dc.subject: COVID-19
2019-nCoV
2019-novel coronavirus
Wuhan Coronavirus
Main protease
Molecular modeling
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: Jun-2020
metadata.artigo.dc.identifier.citation: KANDEEL, M.; AL-NAZAWI, M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sciences, [S.l.], v. 251, June 2020.
metadata.artigo.dc.description.abstract: Aims In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. Materials and methods Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. Key findings COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. Significance The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S0024320520303751
http://repositorio.ufla.br/jspui/handle/1/41079
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.